logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Als Therapy Development Institute


USPTO Granted Patents = 19


Forward Citations = 34

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Fernando G Vieira (13 out of 13 patents)

silverMedal Steven N Perrin (12 out of 12 patents)

bronzeMedal Alan Gill (12 out of 14 patents)

4.  John Monteith Lincecum (9 out of 10 patents)

5.  Bingbing Jiang (5 out of 5 patents)

6.  Cynthia A Gill (5 out of 6 patents)

7.  Anna Gill (3 out of 3 patents)

8.  Alan Premasiri (3 out of 3 patents)

9.  Matvey Lukashev (3 out of 3 patents)

10.  Kyle Denton (3 out of 3 patents)

11.  Alexey Alexandrovich Lugovskoy (2 out of 52 patents)

12.  Alexei Pushechnikov (2 out of 6 patents)

13.  Peter Demin (2 out of 2 patents)

14.  Theo Hatzipetros (1 out of 1 patent)


19 patents:

1. 12617859 - THERAPEUTIC ANTI-CD40 LIGAND ANTIBODIES (2026-05-05),
2. 12522618 - Copper complexes for treatment of neurodegenerative disorders (2026-01-13),
3. 12318365 - Inhibition of dipeptide repeat proteins (2025-06-03),
4. 12275793 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2025-04-14),
5. 12157728 - Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions (2024-12-03),
6. 12012422 - Copper complexes for treatment of neurodegenerative disorders (2024-06-18),
7. 11857534 - Inhibition of dipeptide repeat proteins (2024-01-02),
8. 11708349 - Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions (2023-07-25),
9. 11692040 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2023-07-04),
10. 11660324 - Copper complexes for treatment of neurodegenerative disorders (2023-05-30),
11. 11607402 - Inhibition of dipeptide repeat proteins (2023-03-21),
12. 11384152 - Therapeutic anti-CD40 ligand antibodies (2022-07-12),
13. 11014990 - Anti-CD40L antibodies (2021-05-25),
14. 10683356 - Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies (2020-06-16),
15. 10106618 - Anti-CD40L antibodies (2018-10-23),
Company Overview
The ALS Therapy Development Institute, based in Cambridge, MA, is a nonprofit biotechnology organization dedicated to accelerating the discovery of effective treatments for amyotrophic lateral sclerosis (ALS). The institute specializes in preclinical and clinical research, focusing on drug development and innovative therapeutic approaches. By leveraging advanced technologies and collaborating with academic and industry partners, it aims to transform the landscape of ALS treatment and improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Als Therapy Development Institute USPTO Patent Assignee Logo
19 Patents

#144 in Cambridge, MA

#1,047 in Massachusetts

#17,123 in US

#32,623 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Als Therapy Development Institute

Forward Citations = 34

14 inventors:

goldMedal Fernando G Vieira (13 out of 13 patents)

silverMedal Steven N Perrin (12 out of 12 patents)

bronzeMedal Alan Gill (12 out of 14 patents)

4.  John Monteith Lincecum (9 out of 10 patents)

5.  Bingbing Jiang (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Als Therapy Development Institute. Retrieved from https://idiyas.com/company/als-therapy-development-institute

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…